Morgan Stanley
DOVA

Morgan Stanley’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Morgan Stanley’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,305
Closed -$148K – 6931
2019
Q3 		$148K Sell
5,305
-320,693
-98% -$5.2M ﹤0.01% 5290
2019
Q2 		$4.6M Buy
325,998
+164,761
+102% +$1.57M ﹤0.01% 3000
2019
Q1 		$1.43M Buy
161,237
+140,781
+688% +$1.14M ﹤0.01% 3857
2018
Q4 		$155K Sell
20,456
-135,157
-87% -$2.18M ﹤0.01% 5386
2018
Q3 		$3.26M Sell
155,613
-159,787
-51% -$3.81M ﹤0.01% 3606
2018
Q2 		$9.44M Sell
315,400
-72,066
-19% -$1.96M ﹤0.01% 2444
2018
Q1 		$10.5M Buy
387,466
+175,174
+83% +$5.24M ﹤0.01% 2294
2017
Q4 		$6.12M Buy
212,292
+203,694
+2,369% +$5.58M ﹤0.01% 2880
2017
Q3 		$209K Buy
+8,598
New +$204K ﹤0.01% 5333

Morgan Stanley's DOVA Position: Q4 2019 in Review

Morgan Stanley sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 5,305 shares — an estimated $148K sold.

Morgan Stanley first reported a position in DOVA in Q3 2017 and held it in 9 quarters. The position peaked at $10.5M in Q1 2018. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

  • Morgan Stanley reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Morgan Stanley sold 5,305 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $148K.
  • Morgan Stanley first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
  • Morgan Stanley's Dova Pharmaceuticals, Inc. Common Stock position peaked at $10.5M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Morgan Stanley's 13F filing for Q4 2019, filed 14 Feb 2020.